DCGI Clears Nano-Carrier Vitamin D3 Oral Dispersion by Pulse Pharmaceuticals

Gist - Regulatory Approval: DCGI approved Pulse Pharmaceuticals’ nano-carrier entrapped Vitamin D3 oral dispersion , claimed as a global first for this delivery technology. - Technology: Nano-carrier drug delivery enhances bioavailability and therapeutic efficacy of nutrients/medicines. - Innovation Significance: Demonstrates India’s growing capacity to translate nanoscale research into regulated, patient-ready pharmaceutical products . - UPSC Relevance: Highlights advances in targeted drug delivery , nanotechnology and indigenous pharmaceutical innovation . Background - Regulatory Framework: The Drugs Controller General of India DCGI heads the Central Drugs Standard Control Organisation CDSCO , which regulates pharmaceutical quality, sets standards, and approves specific drug licenses in India. - Limitations of Traditional Oral Drugs: Conventional oral medications frequently suffer from poor solubility and low bio-availability —the fraction of an administered drug that actually enters systemic blood circulation—requiring larger doses to achieve therapeutic effects. - Mechanism of Nano-Pharmaceuticals: Nanotechnology manipulates materials at the nanoscale to construct delivery mechanisms like nano-carriers , which encapsulate the active pharmaceutical ingredient to protect it from digestive degradation and release it precisely where needed. Key Pointers - Maximized Drug Absorption: The primary…